NDA 207865 · Msd Merck CO
Emend
Aprepitant · Oral · Substance P/Neurokinin-1 Receptor Antagonist
Priority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Nov 14, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Dec 17, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
215
62 Phase 3, 9 recruiting
FAERS reports
19,186
17,114 serious, 3,248 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 5, 2024.
EMEND ® for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). EMEND ® is a substance P/neurokinin 1 (NK 1 ) receptor antagonist. EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1 ) EMEND capsules is indicated in combination with other antiemetic agents, in patients 12 years of age and older for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin ( 1 ) nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) ( 1 ) Limitations of Use ( 1 ) EMEND has not been studied for...
Mechanism: Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK 1...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 17, 2015 Original approval · Type 3 - New Dosage Form · priority review LabelReviewPediatric Medical Review
1 products under this application
- EMEND · APREPITANT 125MG/KIT · FOR SUSPENSION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Aprepitant" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataPivotal-lookingCompleted
Jennifer Holder-MurrayAcademic, hospital or other
NCT04606264 · 3,395 participants · Start May 15, 2023 · Primary completion Mar 21, 2025
Drug: Neuraxial Analgesia; Regional Block 1: Paravertebral and 6 more · For: Perioperative Optimization
Sites: Pittsburgh, Pennsylvania · 3 sites in all
- Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.Status unknown
Xijing HospitalAcademic, hospital or other
NCT05755659 · 3,000 participants (planned) · Start Jul 15, 2022 · Primary completion Oct 20, 2024
Drug: Fosaprepitant Dimeglumine for Injection · For: Neoplasms
Sites: Xi'an, China
- Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00619359 · 2,322 participants · Start Feb 2008 · Primary completion Jun 2009
Drug: Comparator: fosaprepitant dimeglumine; Comparator: Aprepitant and 3 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05841849 · 1,028 participants (planned) · Start Jul 2023 · Primary completion Jul 2028
Drug: Aprepitant; Palonosetron and 1 more · For: Breast Cancer; Chemotherapy-induced Nausea and Vomiting
Sites: Hanzhou, China
- Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical TrialPivotal-lookingCompleted
Joseph RoscoeAcademic, hospital or other
NCT00475085 · 1,021 participants · Start Dec 2006 · Primary completion Dec 2012
Drug: aprepitant; dexamethasone and 4 more · For: Nausea
Sites: Mobile, Alabama; Decatur, Illinois; Wichita, Kansas · 16 sites in all
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01594749 · 1,015 participants · Start Sep 24, 2012 · Primary completion Nov 3, 2014
Drug: Fosaprepitant dimeglumine; Fosaprepitant Placebo and 5 more · For: Chemotherapy-Induced Nausea and Vomiting (CINV)
- 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00090246 · 922 participants · Start May 13, 2004 · Primary completion Apr 6, 2005
Drug: MK0869, aprepitant; Comparator: ondansetron IV · For: Postoperative Nausea and Vomiting
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea2,321
- fatigue2,054
- pyrexia1,734
- dyspnoea1,696
- diarrhoea1,674
- vomiting1,605
- off label use1,489
- alopecia1,412
- rash1,330
- hypersensitivity1,248
- decreased appetite1,172
- pruritus1,138
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 127 |
| 2005 | 134 |
| 2006 | 145 |
| 2007 | 181 |
| 2008 | 177 |
| 2009 | 216 |
| 2010 | 351 |
| 2011 | 479 |
| 2012 | 764 |
| 2013 | 691 |
| 2014 | 818 |
| 2015 | 1,057 |
| 2016 | 1,325 |
| 2017 | 894 |
| 2018 | 1,376 |
| 2019 | 1,393 |
| 2020 | 1,186 |
| 2021 | 1,275 |
| 2022 | 1,170 |
| 2023 | 1,246 |
| 2024 | 1,848 |
| 2025 | 1,439 |
| 2026 | 894 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Apr 8, 2026
Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03). To be discontinued in approximately early-September 2026.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Emend (Aprepitant)
2024 spending
$123K
Beneficiaries
15
49 claims
Per beneficiary
$8,193
$253.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $54,636 |
| 2021 | $28,372 |
| 2022 | $76,475 |
| 2023 | $61,588 |
| 2024 | $122,902 |
Part D: Emend (Fosaprepitant Dimeglumine)
2024 spending
$7K
Beneficiaries
n/a
21 claims
Per beneficiary
n/a
$193.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $48,894 |
| 2021 | $5,848 |
| 2022 | $2,438 |
| 2023 | $0 |
| 2024 | $7,355 |
Part B: Emend* (Fosaprepitant Dimeglumine*) · HCPCS J1453
2024 spending
$2.2M
Beneficiaries
21,354
104,356 claims
Per beneficiary
$103
2024 ASP limit $0.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $51,275,458 |
| 2021 | $13,921,518 |
| 2022 | $2,823,785 |
| 2023 | $2,419,136 |
| 2024 | $2,206,841 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- A Systematic Review on Cannabis Hyperemesis Syndrome and Its Management Options.
Senderovich H, Patel P, Jimenez Lopez B, et al. · Med Princ Pract 2022 · Systematic Review
- [Update on PONV-What is new in prophylaxis and treatment of postoperative nausea and vomiting? : Summary of recent consensus recommendations and Cochrane reviews on prophylaxis and treatment of postoperative nausea and vomiting].
Kienbaum P, Schaefer MS, Weibel S, et al. · Anaesthesist 2022 · Meta-Analysis, Review
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: an abridged Cochrane network meta-analysis.
Weibel S, Schaefer MS, Raj D, et al. · Anaesthesia 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Navari RM, Qin R, Ruddy KJ, et al. · N Engl J Med 2016 · Comparative Study, Randomized Controlled Trial
- Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.